Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5 Oncol Ther (2017) 5:31–40 DOI 10.1007/s40487-016-0037-8 ORIGINAL RESEARCH The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5 . . . Steve Schey Luis Felipe Casado Montero Chloe Stengel-Tosetti Craig J. Gibson Sujith Dhanasiri Received: October 24, 2016 / Published online: January 3, 2017 The Author(s) 2016. This article is published with open access at Springerlink.com on treatment duration and time to progression ABSTRACT (TTP) (taken from trial data). We compared a Introduction: Lenalidomide is an active agent baseline scenario (of current lenalidomide that was approved for use in the EU in 2015 as a uptake) with two alternative future scenarios. first-line therapy for previously untreated, Future Scenario A used an increased uptake of non-transplant eligible multiple myeloma first-line lenalidomide: up to 50% in Year 5. patients. Our objective was to assess the cost Future Scenario B was similar to the baseline, impact of lenalidomide when selected as a but included a 20% increased uptake of the first-line treatment for transplant-ineligible triple therapy regimen, carfilzomib, patients in France, Germany, Italy, Spain, and lenalidomide, and dexamethasone (KRd) at the United Kingdom (EU5). second line. Methods: We developed a cost-impact model of Results: Compared to alternative first-line care http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

Loading next page...
 
/lp/springer-journals/the-cost-impact-of-lenalidomide-for-newly-diagnosed-multiple-myeloma-0C0G12YD4a
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0037-8
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2017) 5:31–40 DOI 10.1007/s40487-016-0037-8 ORIGINAL RESEARCH The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5 . . . Steve Schey Luis Felipe Casado Montero Chloe Stengel-Tosetti Craig J. Gibson Sujith Dhanasiri Received: October 24, 2016 / Published online: January 3, 2017 The Author(s) 2016. This article is published with open access at Springerlink.com on treatment duration and time to progression ABSTRACT (TTP) (taken from trial data). We compared a Introduction: Lenalidomide is an active agent baseline scenario (of current lenalidomide that was approved for use in the EU in 2015 as a uptake) with two alternative future scenarios. first-line therapy for previously untreated, Future Scenario A used an increased uptake of non-transplant eligible multiple myeloma first-line lenalidomide: up to 50% in Year 5. patients. Our objective was to assess the cost Future Scenario B was similar to the baseline, impact of lenalidomide when selected as a but included a 20% increased uptake of the first-line treatment for transplant-ineligible triple therapy regimen, carfilzomib, patients in France, Germany, Italy, Spain, and lenalidomide, and dexamethasone (KRd) at the United Kingdom (EU5). second line. Methods: We developed a cost-impact model of Results: Compared to alternative first-line care

Journal

Oncology and TherapySpringer Journals

Published: Jan 3, 2017

References